GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Retained Earnings

Keymed Biosciences (HKSE:02162) Retained Earnings : HK$-6,179.2 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Keymed Biosciences's retained earnings for the quarter that ended in Dec. 2023 was HK$-6,179.2 Mil.

Keymed Biosciences's quarterly retained earnings increased from Dec. 2022 (HK$-5,907.4 Mil) to Jun. 2023 (HK$-5,734.7 Mil) but then declined from Jun. 2023 (HK$-5,734.7 Mil) to Dec. 2023 (HK$-6,179.2 Mil).

Keymed Biosciences's annual retained earnings declined from Dec. 2021 (HK$4,470.3 Mil) to Dec. 2022 (HK$-5,907.4 Mil) and declined from Dec. 2022 (HK$-5,907.4 Mil) to Dec. 2023 (HK$-6,179.2 Mil).


Keymed Biosciences Retained Earnings Historical Data

The historical data trend for Keymed Biosciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences Retained Earnings Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
-307.12 -1,297.55 4,470.28 -5,907.43 -6,179.16

Keymed Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only 4,470.28 - -5,907.43 -5,734.74 -6,179.16

Keymed Biosciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Keymed Biosciences  (HKSE:02162) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Keymed Biosciences (HKSE:02162) Business Description

Traded in Other Exchanges
Address
No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.
Executives
Chen Bo 2201 Interest of corporation controlled by you
Eagle Hero Management Limited 2101 Beneficial owner
Trident Trust Company (hk) Limited 2301 Trustee
Moonshot Holdings Limited 2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences (HKSE:02162) Headlines

No Headlines